Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
WAT Catalyst Timeline
Dated clinical, regulatory and corporate events for Waters Corporation
Catalyst Timeline
Dated clinical, regulatory & corporate events for Waters Corporation
Upcoming catalysts 2
Event history 50
Past FDA Catalysts and PDUFA Decisions
How WAT actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Drug Pipeline Intelligence
No drug pipeline
Waters Corporation is a diagnostics company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every WAT program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| KUEBLER CHRISTOPHER ADirector | Option | 3,626 21,434 held | $136.43 | 08/06/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in WAT
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 1 % | 59.32 M | 135.00 K |
Ownership Trends
WAT Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How WAT ranks across every disease it competes in
WAT News
Waters Corporation to Present at the 9th Annual Evercore Healthcare Conference
Waters Corporation announced that CEO Udit Batra will participate in a fireside chat at the 9th Annual Evercore Healthcare Conference on December 1, 2026. The event will be accessible via a live webcast, which will also be available for replay for 90 days. The company continues to focus on advancing life sciences through innovative technologies.
Read more →Waters Achieves FDA 510(k) Clearance for Ready-to-Use Flow Cytometry Clinical Tests for Leukemia and Lymphoma
Waters Corporation announced FDA 510(k) clearance for the BD OneFlow LST and B-CLPD T1 Tests, which aid in diagnosing B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. These tests provide 96.3% sensitivity and 98.2% specificity, while significantly reducing manual steps in the testing process. They are set to be commercially available in spring 2027.
Read more →Waters Corporation (NYSE: WAT) Reports Third Quarter 2026 Financial Results
Waters Corporation reported third quarter 2026 revenue of $1.767 billion, exceeding guidance. Adjusted EPS rose 21% to $4.10, driven by strong growth in both Analytical Sciences and Biosciences divisions. The company raised its full-year revenue guidance by $43 million, citing new growth vectors. Additionally, Waters announced the acquisition of MOBILion Systems, enhancing its capabilities in proteomics.
Read more →Waters Acquires MOBILion Systems, Bringing Advanced Ion-Mobility Separation to its Mass Spectrometry Portfolio with the Speed and Resolution AI Workflows Require for Proteomics Biomarker Discovery
Waters Corporation has acquired MOBILion Systems to enhance its mass spectrometry portfolio with SLIM high-resolution ion mobility technology. This acquisition aims to accelerate Waters' entry into the proteomics market, improving molecular analysis and supporting AI-driven research. The integration of SLIM technology is expected to advance clinical applications for biomarker discovery and blood-based diagnostics.
Read more →Waters Launches AI-Powered Peak Integration Expanding its Suite of Premium AI Subscription Capabilities for Empower Software
Waters Corporation has launched AI-Powered Peak Integration, enhancing its Empower Software for chromatography data processing. This new feature significantly reduces manual interventions by up to 95% and improves accuracy by 76%. It aims to support regulated laboratories in speeding up drug development while maintaining data integrity. Early access for customers begins in December 2026.
Read more →Waters and Labcorp to Expand Access to Cervical Cancer Screening with the Most Comprehensive FDA-Approved HPV Testing Option Beginning in Late 2026
Waters Corporation and Labcorp announced a partnership to provide the FDA-approved BD Onclarity HPV Assay, enhancing cervical cancer screening access. This initiative aims to address screening gaps by offering both clinician-collected and self-collected testing options. The assay supports all ASCCP guidelines and provides extensive genotyping, making it a significant advancement in cervical cancer prevention.
Read more →Waters Corporation and Quest Diagnostics Help Close Cervical Cancer Screening Gap Bringing Nationwide Access to the Most Comprehensive FDA-Cleared At-Home HPV Screening Option
Waters Corporation and Quest Diagnostics announced a collaboration to expand access to the FDA-cleared Onclarity Self-Collection Kit for HPV testing. Starting in 2027, Quest will distribute the at-home kit through its national clinician, health plan, and consumer channels. This initiative targets the 24 million un- and under-screened individuals in the U.S. by offering a convenient, comprehensive screening option.
Read more →Ultima Genomics Selected for Landmark Large-Scale Immune Profiling Study with IMU Biosciences, UK Biobank and Waters Corporation
Ultima Genomics has been selected to provide its UG200 Sequencing Platform for a large-scale immune profiling study in collaboration with IMU Biosciences and UK Biobank. The study aims to analyze 80,000 blood samples, contributing to a comprehensive dataset that will enhance understanding of the human immune system. This initiative is expected to expand to a total of 500,000 samples, facilitating advanced research into immune-related diseases.
Read more →Waters Launches AI Link, Advancing AI-Enabled LC-MS Workflows from Research to Release
Waters Corporation has launched Waters AI Link, a new software capability that integrates AI into laboratory workflows. This innovation allows for AI-directed experiments to transition seamlessly from research to regulated environments, enhancing efficiency and reducing timelines. The company has also joined Anthropic's Model Hardware Standard program, facilitating autonomous operation of laboratory instruments. This advancement positions Waters as a leader in the AI transformation of laboratory processes.
Read more →Waters Corporation Schedules Third Quarter 2026 Earnings Conference Call
Waters Corporation has announced its Q3 2026 earnings conference call scheduled for November 3, 2026. The call will begin at 8:00 a.m. Eastern Time and will be available via a live webcast. A replay of the presentation will be accessible until December 1, 2026.
Read more →Waters Sets Benchmark for Standardized Spectral Flow Cytometry with Commercial Launch of BD FACSDiscover A7 Cell Analyzer
Waters Corporation has launched the BD FACSDiscover A7 Cell Analyzer, enhancing flow cytometry capabilities with advanced spectral resolution and standardization. This new device allows researchers to conduct experiments with over 50 parameters, improving data consistency across different users and instruments. The analyzer is designed to facilitate immunology research and drug development, making advanced technologies more accessible.
Read more →Waters Corporation to Present at the J.P. Morgan U.S. All Stars Conference
Waters Corporation will have its CEO, Udit Batra, participate in a fireside chat at the J.P. Morgan U.S. All Stars Conference on September 23, 2026. The event will be webcast live and available for replay for 90 days. This participation underscores Waters' commitment to engaging with investors and stakeholders.
Read more →Wellinks Appoints Andrew Agwunobi and Mike Waters to Board of Directors and Expands Management Team
Wellinks has appointed Andrew Agwunobi and Mike Waters to its Board of Directors, alongside three new leadership roles. These appointments aim to enhance the company's operational excellence and support its growth in virtual cardiopulmonary care. The new leaders bring extensive experience in healthcare and technology to strengthen Wellinks' impact on patient care.
Read more →Waters Corporation to Present at the Wells Fargo Healthcare Conference
Waters Corporation announced that its CEO, Udit Batra, will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on September 9, 2026. The event will be available via live webcast, with a replay accessible for 90 days. This participation underscores Waters' leadership in life sciences and commitment to innovation.
Read more →Waters Corporation (NYSE: WAT) Reports Second Quarter 2026 Financial Results
Waters Corporation reported strong financial results for Q2 2026, with total revenue of $1.645 billion, surpassing guidance. Organic revenue grew by 9% in constant currency, driven by significant growth in the Analytical Sciences Division. The company raised its full-year guidance, reflecting positive market conditions and effective execution of its growth strategy. However, GAAP EPS showed a loss due to acquisition-related costs.
Read more →Waters Launches Industry's Most Sensitive and Robust Clinical IVD System with Xevo TQ Absolute XR IVD Mass Spectrometer
Waters Corporation has launched the Xevo TQ Absolute XR IVD Mass Spectrometer, enhancing its MassTrak IVD System portfolio. This new system offers five times greater sensitivity than its competitors, improving analytical performance for complex biological samples. It is designed for routine laboratory testing in women's health, cancer assessment, and toxicology, promising to boost laboratory productivity and reliability.
Read more →Waters Corporation Schedules Second Quarter 2026 Earnings Conference Call
Waters Corporation has announced its Q2 2026 earnings conference call scheduled for August 4, 2026. The call will take place at 8:00 a.m. Eastern Time, with a live webcast available on the company's Investor Relations website. A replay of the call will be accessible until September 1, 2026.
Read more →SNT Biotech Announces a Partnership with Waters Corporation to Bring the Most Comprehensive FDA-Cleared At-Home HPV Cervical Cancer Screening Tool Available in the U.S. Today to Patients
SNT Biotech has partnered with Waters Corporation to enhance access to at-home cervical cancer screenings through the FDA-cleared Onclarity™ HPV Self-Collection Kit. This initiative aims to address the significant barriers to screening faced by underserved populations, with a focus on improving completion rates and early detection of cervical cancer. The partnership combines education and infrastructure to facilitate better health outcomes for women.
Read more →IMU Biosciences Selects Waters to Advance Breakthrough AI Immune Mapping Platform to Transform Early Diagnosis, Monitoring, and Precision Medicine
IMU Biosciences has partnered with Waters Corporation to enhance its AI-driven immune mapping platform. This collaboration aims to analyze over 100 million data points from a single blood sample, improving early diagnosis and precision medicine. The partnership will leverage Waters' advanced technologies to expand IMU's immune dataset and establish new standards in immune profiling.
Read more →HighRes® and Waters Collaborate to Advance Drug Discovery through Robotic Automation
Waters Corporation is collaborating with HighRes® to enhance drug discovery processes through robotic automation. This partnership aims to streamline workflows and improve efficiency in pharmaceutical research. The collaboration highlights the ongoing trend of integrating advanced technologies in drug development.
Read more →